"It is essential that a COVID-19 vaccine can be effective across a broad age range, particularly in older individuals where they are disproportionately at risk of severe COVID-19 disease".
Based on these interim safety and efficacy data, Moderna intends to submit for an Emergency Use Authorisation (EUA) with the US Food and Drug Administration (USFDA) in the coming weeks and anticipates having the EUA informed by the final safety and efficacy data.More news: Floyd Mayweather Slams Logan Paul After Disrespectful Interview
The chairman of the multinational company said- We had given the vaccine to 81 people out of 99 employees working in one of our offices located overseas, after outbreak of corona in the office it was found that none of the people who were given the vaccine got infected, But 10 of the 18 non-vaccinated people were infected.
Two vaccine candidates are developed by Sinopharm's subsidiary China National Biotec Group (CNBG), and the third is developed by Sinovac Biotech. The data from an emergency program is inefficient and unable to determine a vaccine's effectiveness.More news: Hawaii imposes new COVID-19 travel restrictions
The department has also been authorized to make necessary recommendations to provide import licenses to the firms or institutions to import vaccines as per the ordinance. He had emphasised that vaccination of Russians against coronavirus was the top priority and is more important than the export of vaccines.
The ongoing phase 3 trial is assessing the vaccine for its effectiveness, or in other words, whether it can protect people from COVID-19. 40,000 participants have had blood samples taken upon being administered the second dose, said Jingzhen. "Our progress so far, from research and development to clinical trials and production and emergency use, is leading the world in all aspects", he said without offering evidence.
Global trials are expected to begin in Uzbekistan late this month, followed by trials in Indonesia, Pakistan and Ecuador. Pfizer and BioNTech then followed by Wednesday and said their candidate was in fact 95 percent effective against COVID-19 as well.More news: Mercedes-Maybach S-Class unveiled as new luxury flagship
Early trial results of Oxford's COVID-19 vaccine have shown that it produces an immune response against the virus and is safe for older adults.